Natera Inc
NTRA154.890USD
+1.899+1.24%
收盘 04/29, 16:00（美东）报价延迟15分钟
20.55B总市值
亏损市盈率 TTM
关于 Natera Inc 公司
Natera, Inc. 是一家诊断公司，专注于分子检测服务的开发和商业化，将其技术应用于女性健康、肿瘤学和器官健康领域。其无细胞脱氧核糖核酸 (cfDNA) 技术结合了其分子检测，可从小到单细胞的样本中可靠地测量整个基因组的许多信息区域。该公司的产品包括 Panorama 无创产前检测 (NIPT)、Vistara、Horizon 携带者筛查、Spectrum 植入前遗传学、Anora 流产检测、Empower 和 Prospera。该公司还提供 Constellation，这是一个基于云的软件平台，使实验室客户能够通过云访问公司的算法和生物信息学，以验证和启动基于公司技术的测试。其 NIPT 可筛查胎儿和双胞胎妊娠的染色体异常，通常需要从母亲抽血。
公司简介
公司代码NTRA
公司名称Natera Inc
上市日期Jul 02, 2015
成立日期2007
CEOMr. Steven Leonard (Steve) Chapman
员工数量4424
证券类型Ordinary Share
年结日Jul 02
公司地址13011 Mccallen Pass
城市AUSTIN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编78753
电话16502499090
网址https://www.natera.com/
公司代码NTRA
上市日期Jul 02, 2015
成立日期2007
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Matthew Rabinowitz, Ph.D.
Dr. Matthew Rabinowitz, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.37M
+1.01%
Mr. Roelof Frederick Botha
Mr. Roelof Frederick Botha
Lead Independent Director
Lead Independent Director
1.23M
-6.87%
Mr. Jonathan Sheena
Mr. Jonathan Sheena
Co-Founder, Director
Co-Founder, Director
327.94K
-0.90%
Mr. Daniel A Rabinowitz
Mr. Daniel A Rabinowitz
Secretary, Chief Legal Officer
Secretary, Chief Legal Officer
174.95K
+0.22%
Mr. John Fesko
Mr. John Fesko
President, Chief Business Officer
President, Chief Business Officer
92.34K
-0.37%
Mr. Solomon Moshkevich
Mr. Solomon Moshkevich
President - Clinical Diagnostics
President - Clinical Diagnostics
67.13K
-4.68%
Herman Rosenman ,CPA
Herman Rosenman ,CPA
Independent Director
Independent Director
62.93K
-4.50%
Dr. James I. (Jim) Healy, M.D., Ph.D.
Dr. James I. (Jim) Healy, M.D., Ph.D.
Independent Director
Independent Director
43.15K
-0.49%
Mr. Steven Leonard (Steve) Chapman
Mr. Steven Leonard (Steve) Chapman
Chief Executive Officer, Director
Chief Executive Officer, Director
33.38K
-29.81%
Mr. Michael Burkes Brophy
Mr. Michael Burkes Brophy
Chief Financial Officer
Chief Financial Officer
14.49K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Matthew Rabinowitz, Ph.D.
Dr. Matthew Rabinowitz, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.37M
+1.01%
Mr. Roelof Frederick Botha
Mr. Roelof Frederick Botha
Lead Independent Director
Lead Independent Director
1.23M
-6.87%
Mr. Jonathan Sheena
Mr. Jonathan Sheena
Co-Founder, Director
Co-Founder, Director
327.94K
-0.90%
Mr. Daniel A Rabinowitz
Mr. Daniel A Rabinowitz
Secretary, Chief Legal Officer
Secretary, Chief Legal Officer
174.95K
+0.22%
Mr. John Fesko
Mr. John Fesko
President, Chief Business Officer
President, Chief Business Officer
92.34K
-0.37%
Mr. Solomon Moshkevich
Mr. Solomon Moshkevich
President - Clinical Diagnostics
President - Clinical Diagnostics
67.13K
-4.68%
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Insurance carriers
1.57B
92.63%
Laboratory and other partners
97.21M
5.73%
Patients
27.88M
1.64%
地区USD
名称
营收
占比
United States
1.66B
97.69%
Europe, Middle East, India, Africa
23.88M
1.41%
Asia Pacific and Other
8.66M
0.51%
Americas, excluding U.S
6.62M
0.39%
业务
地区
业务USD
名称
营收
占比
Insurance carriers
1.57B
92.63%
Laboratory and other partners
97.21M
5.73%
Patients
27.88M
1.64%
股东统计
更新时间: 4月16日 周三
更新时间: 4月16日 周三
持股股东
股东类型
持股股东
股东统计
占比
The Vanguard Group, Inc.
9.04%
T. Rowe Price Associates, Inc.
4.89%
BlackRock Institutional Trust Company, N.A.
4.76%
JP Morgan Asset Management
4.31%
Farallon Capital Management, L.L.C.
3.26%
Other
73.74%
持股股东
股东统计
占比
The Vanguard Group, Inc.
9.04%
T. Rowe Price Associates, Inc.
4.89%
BlackRock Institutional Trust Company, N.A.
4.76%
JP Morgan Asset Management
4.31%
Farallon Capital Management, L.L.C.
3.26%
Other
73.74%
股东类型
股东统计
占比
Investment Advisor/Hedge Fund
37.24%
Investment Advisor
31.23%
Hedge Fund
16.26%
Individual Investor
3.26%
Family Office
2.73%
Family Office
2.73%
Family Office
2.69%
Research Firm
1.53%
Bank and Trust
1.40%
Other
0.93%
机构持股
更新时间: 1月20日 周一
更新时间: 1月20日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q1
1008
128.74M
95.25%
+14.58K
2024Q4
1001
128.40M
95.17%
-537.76K
2024Q3
896
125.06M
100.75%
-6.81M
2024Q2
850
125.13M
101.89%
-7.92M
2024Q1
798
124.30M
101.71%
-6.12M
2023Q4
781
119.55M
99.60%
-13.66M
2023Q3
787
122.52M
102.97%
-5.30M
2023Q2
792
116.72M
102.40%
-10.10M
2023Q1
788
115.81M
102.22%
-9.06M
2022Q4
777
112.51M
103.76%
+3.33M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
12.29M
9.09%
+878.30K
+7.70%
Dec 31, 2024
T. Rowe Price Associates, Inc.
6.65M
4.92%
+3.88M
+140.19%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
6.47M
4.78%
+285.61K
+4.62%
Dec 31, 2024
JP Morgan Asset Management
5.86M
4.34%
+1.78M
+43.64%
Dec 31, 2024
Farallon Capital Management, L.L.C.
4.43M
3.28%
-125.70K
-2.76%
Dec 31, 2024
Duquesne Family Office LLC
3.57M
2.64%
--
--
Dec 31, 2024
Wellington Management Company, LLP
3.24M
2.4%
+439.78K
+15.70%
Dec 31, 2024
Fred Alger Management, LLC
3.02M
2.23%
-994.18K
-24.78%
Dec 31, 2024
State Street Global Advisors (US)
2.99M
2.21%
-503.37K
-14.41%
Dec 31, 2024
RTW Investments L.P.
2.59M
1.92%
--
--
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
Global X Genomics & Biotechnology ETF
6.13%
Alger Mid Cap 40 ETF
6.07%
Invesco Dorsey Wright Healthcare Momentum ETF
5.71%
ARK Genomic Revolution ETF
5.41%
Franklin Genomic Advancements ETF
5.14%
First Trust Nasdaq Lux Digi Health Solutions ETF
5.04%
Invesco Biotechnology & Genome ETF
4.72%
Alger 35 ETF
4.36%
VanEck Biotech ETF
4.23%
WisdomTree BioRevolution Fund
3.67%
查看更多
Global X Genomics & Biotechnology ETF
占比6.13%
Alger Mid Cap 40 ETF
占比6.07%
Invesco Dorsey Wright Healthcare Momentum ETF
占比5.71%
ARK Genomic Revolution ETF
占比5.41%
Franklin Genomic Advancements ETF
占比5.14%
First Trust Nasdaq Lux Digi Health Solutions ETF
占比5.04%
Invesco Biotechnology & Genome ETF
占比4.72%
Alger 35 ETF
占比4.36%
VanEck Biotech ETF
占比4.23%
WisdomTree BioRevolution Fund
占比3.67%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据